Recent Press Releases

September 28, 2023

Fabre-Kramer Pharmaceuticals Announces FDA Approval of EXXUA™, the First and Only Oral Selective 5HT1a Receptor Agonist for the Treatment of Major Depressive Disorder in Adults

─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━

January 24, 2023

Fabre-Kramer Pharmaceuticals Announces FDA Acceptance of NDA Resubmission as Complete Response and Assignment of PDUFA Regulatory Action Date

─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━

January 4, 2023

Fabre-Kramer Submits NDA Amendment for EXXUA™ for Treatment of Major Depressive Disorder

─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━

January 3, 2018

Mission Pharmacal to Manufacture Fabre-Kramer’s Novel Antidepressant Travivo™ (Gepirone HCl) Extended Released Tablets

─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━

October 20, 2016

Antidepressants Worsen Sexual Dysfunction and Depression?

─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━

October 13, 2016

Patient Experience Demonstrates Pressing Need for New Treatment Options

─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━

March 13, 2016

Travivo™ Demonstrates Substantial Evidence of Effectiveness in Treatment of Major Depressive Disorders

─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━─━

December 2, 2015

Office of New Drugs Director John Jenkins M.D. will review Gepirone data and analysis